Similar articles

• [Immunologic capacity of cancer patients and BCG-CSW immunotherapy].

  Yasumoto K, Manabe H, Yanagawa E, Nagano S, Ueda H. Yasumoto K, et al. Nihon Kyobu Geka Gakkai Zasshi. 1979 Apr;27(4):449-51. Nihon Kyobu Geka Gakkai Zasshi. 1979. PMID: 381535 Japanese. No abstract available.
• [Cancer immunotherapy with BCG cell-wall skeleton (author's transl)].

  Azuma I, Yamamura Y. Azuma I, et al. Tanpakushitsu Kakusan Koso. 1978 May;23(6):625-40. Tanpakushitsu Kakusan Koso. 1978. PMID: 211546 Review. Japanese. No abstract available.
• [Immunotherapy with BCG-CWS (cell-wall skeleton) in patients with primary lung cancer (author's transl)].

  Takano T, Morishita M, Yamamoto M, Yamagata K, Takada K. Takano T, et al. Nihon Kyobu Shikkan Gakkai Zasshi. 1977 Nov;15(11):769-74. Nihon Kyobu Shikkan Gakkai Zasshi. 1977. PMID: 606901 Japanese. No abstract available.
• [Treatment of advanced primary lung cancer, particularly immunotherapy with BCG-CWS (author's transl)].

  Ohta M, Iida A, Ueda H, Yasumoto K, Manabe H. Ohta M, et al. Kyobu Geka. 1977 Jul;30(7):581-5. Kyobu Geka. 1977. PMID: 904107 Japanese. No abstract available.
• [Immunotherapy of cancer with BCG].

  Yamamura Y, Azuma I. Yamamura Y, et al. Nihon Rinsho. 1974 Mar;32(3):542-53. Nihon Rinsho. 1974. PMID: 4603604 Review. Japanese. No abstract available.